Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)
Grant
Overview
Affiliation
Overview
Date/time Interval
May 1, 2016 - June 30, 2023
Awarded By
MASSACHUSETTS GENERAL HOSPITAL
Total Award Amount
27344.00
Direct Costs
18601.00
Sponsor Award Id
Affiliation
Contributor
Marissa Dean
Investigator
Victor Sung
Principal Investigator